TITLE

Emergence of the Precore Mutant Late in Chronic Hepatitis B Infection Correlates With the Severity of Liver Injury and Mutations in the Core Region

AUTHOR(S)
Maruyama, Toshiyuki; Mitsui, Hiroshi; Maekawa, Hisato; Yamada, Haruki; Hirayama, Miki; Iino, Shiro; Yasuda, Kiyomi; Koike, Kazuhiko; Kimura, Satoshi; Milich, David R.
PUB. DATE
October 2000
SOURCE
American Journal of Gastroenterology;Oct2000, Vol. 95 Issue 10, p2894
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
OBJECTIVE; The reason that precore negative mutants (e-minus DNA) gradually become predominant in some patients during chronic hepatitis B virus infection is not clear. Theoretically, as long as both e-plus and e minus DNA share the same epitopes in the core region, HBcAg-specific cytotoxic T lymphocytes (CTLs) cannot distinguish between the target peptides expressed by e-plus and e-minus DNA. Therefore, e-minus DNA may be accompanied by additional mutations in the core region, which may affect cytotoxic T lymphocyte recognition. To examine this possibility, the sequences of the precore and the entire core region of the hepatitis B virus genome were analyzed from paired serum samples in CH-B patients who experienced HBeAg to anti-HBe seroconversion (SC). METHODS: Patients were divided into two groups. Group A patients (n = 17) genome-converted to e-minus DNA in the precore region, which abolished HBeAg secretion within 3-4 yr after SC. Group B patients (n = 16) retained precore wild-type DNA for more than 3-4 yr after SC, To investigate the impact of the emergence of precore mutant type DNA on liver injury, alanine aminotransferase (ALT) levels were also examined. RESULTS: ALT flares were more severe among patients in group A than in group B. The average mean ALT level during the HBeAg negative phase of chronic infection was 54 ± 38 in group A and 28 ± 24 in group B. The average maximal ALT level during the HBeAg negative phase was 235 ± 249 in group A and 83 ± 106 in group B, Furthermore, all 17 patients in group A developed new core mutants during genome conversion. The average number of mutations in the core gene was 0.9 ± 1.2 before genome conversion (e-plus DNA dominant phase) and increased to 2.8 ± 1.3 for the 3-4 yr during genome conversion (e-minus DNA dominant phase). In contrast, only 56% (nine of 16) of patients in group B developed new core mutations after the loss of HBeAg. The average number of mutations in the core gene was 1.8 ± 1.3 before SC (HBeAg-positive and e-plus DNA dominant phase), and decreased to 1.1 ± 1.1 for 3-4 yr after seroconversion (anti-HBe-positive and e-plus DNA dominant phase). CONCLUSIONS: These data indicate that the emergence of a predominant precore negative genotype late in chronic hepatitis B virus infection is associated with the selection of additional mutations in the core gene, as well as with liver injury.
ACCESSION #
17624216

 

Related Articles

  • The Relationship of Hepatitis B e Antigen, DNA Polymerase Activity, and Titer of Hepatitis B Surface Antigen with Ongoing Liver Injury in Chronic Hepatitis B Virus Infection. Perrillo, R.; Campbell, C.; Wellinghoff, W.; Gelb, L. // American Journal of Gastroenterology;Jul1982, Vol. 77 Issue 7, p445 

    The purpose of this study was to examine the association of circulating viral markers with ongoing liver disease in chronic hepatitis B virus infection. Hepatitis B e antigen (HBeAg) was significantly more likely to be associated with abnormal alanine aminotransferase (ALT) activity than was...

  • Association of CD4+CD25+Foxp3+ regulatory T cells with chronic activity and viral clearance in patients with hepatitis B. Guilin Yang; Ailian Liu; Qing Xie; Taylor B. Guo; Bing Wan; Boping Zhou; Jingwu Z. Zhang // International Immunology;Feb2007, Vol. 19 Issue 2, p133 

    Chronic activity of hepatitis B is thought to involve aberrant immune tolerance of unknown mechanism. In this study, we examined the role of CD4+CD25+Foxp3+ regulatory T cells in disease activity and viral clearance in hepatitis B. Patients with chronic active hepatitis B (CAH) and asymptomatic...

  • Current treatment of hepatitis B. Dusheiko, G.; Antonakopoulos, N. // Gut;Jan2008, Vol. 57 Issue 1, p105 

    The article offers information on the current treatment of Hepatitis B. It states that Hepatitis B is usually determined by the identification of HBsAg in serum. Moreover, the detection of viral DNA is the most particular method of establishing Hepatitis B viraenemia, and that standardized...

  • Factors associated with spontaneous HBsAg clearance in chronic hepatitis B patients followed at a university hospital. Ferreira, Sandro C.; Chachá, Silvana G. F.; Souza, Fernanda F.; Teixeira, Andreza C.; Santana, Rodrigo C.; Villanova, Márcia G.; Zucoloto, Sérgio; Ramalho, Leandra N.; Perdoná, Gleici S. C.; Passos, Afonso D. C.; Martinelli, Ana L. C. // Annals of Hepatology: Official Journal of the Mexican Associatio;Nov/Dec2014, Vol. 13 Issue 6, p762 

    Introduction. Few studies have evaluated the factors involved in the spontaneous HBsAg seroclearance in patients with chronic hepatitis B (HBV) followed up on a long-term basis from areas with a low prevalence of HBV infection. We aimed to determine the rate of spontaneous HBsAg seroclearance...

  • Persistent Hepatitis B Viral Replication in a FVB/N Mouse Model: Impact of Host and Viral Factors. Shih-Hui Chen; Hui-Lin Wu; Jia-Horng Kao; Lih-Hwa Hwang // PLoS ONE;May2012, Vol. 7 Issue 5, p1 

    The mechanism underlying the chronicity of hepatitis B virus (HBV) infection has long been an interesting question. However, this mechanism remains unclear largely due to the lack of an animal model that can support persistent HBV replication and allow for the investigation of the relevant...

  • Hepatitis B reactivation after withdrawal of preemptive lamivudine in patients with haematological malignancy on completion of cytotoxic chemotherapy. Hui, C. -K.; Cheung, W. W. W.; Au, W. Y.; Lie, A. K. W.; Zhang, H. -Y.; Yueng, Y. -H.; Wong, B. C. Y.; Leung, N.; Kwong, Y. -L.; Liang, R.; Lau, G. K. K. // Gut;Nov2005, Vol. 54 Issue 11, p1597 

    Background: The hepatic outcome of hepatitis B surface antigen (HBsAg) positive patients undergoing chemotherapy after withdrawal of pre-emptive lamivudine is unknown. Aims: To examine the occurrence of hepatitis B virus (HBV) reactivation after withdrawal of pre-emptive lamivudine. Methods:...

  • PD-1 Blockage Reverses Immune Dysfunction and Hepatitis B Viral Persistence in a Mouse Animal Model. Tzeng, Horng-Tay; Tsai, Hwei-Fang; Liao, Hsiu-Jung; Lin, Yi-Jiun; Chen, Lieping; Chen, Pei-Jer; Hsu, Ping-Ning // PLoS ONE;Jun2012, Vol. 7 Issue 6, p1 

    Persistent hepatitis B viral (HBV) infection results in chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma (HCC). Recent studies in animal models of viral infection indicate that the interaction between the inhibitory receptor, programmed death (PD)-1, on lymphocytes and its ligand...

  • Changes to the Natural Killer Cell Repertoire after Therapeutic Hepatitis B DNA Vaccination. Scott-Algara, Daniel; Mancini-Bourgine, Maryline; Fontaine, Hélène; Pol, Stanislas; Michel, Marie-Louise // PLoS ONE;2010, Vol. 5 Issue 1, p1 

    Background: Improvements to the outcome of adaptive immune responses could be achieved by inducing specific natural killer (NK) cell subsets which can cooperate with dendritic cells to select efficient T cell responses. We previously reported the induction or reactivation of T cell responses in...

  • Telbivudine. Keam, Susan J. // Drugs;2007, Vol. 67 Issue 13, p1917 

    Telbivudine, the unmodified L-nantiomer of the naturally occurring nucleoside D-thymidine, is a potent synthetic nucleoside analogue. It acts as a hepatitis B virus (HBV) polymerase inlubitor and preferentially inhibits HBV second strand (DNA-dependent) compared with first strand (RNA-dependent)...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics